|Mr. Joseph Truitt||Pres, CEO & Director||773.77k||N/A||1965|
|Mr. Paul Firuta||Exec. VP & COO||462.03k||N/A||1966|
|Mr. Anthony S. Gibney||Exec. VP & Chief Bus. Officer||408.66k||N/A||1971|
|Dr. Steven L. Zelenkofske||Exec. VP & Chief Medical Officer||314.81k||N/A||1959|
|Mr. Brian R. Di Donato||CFO, SVP & Treasurer||N/A||N/A||1967|
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in Blue Bell, Pennsylvania. As of January 28, 2020, Achillion Pharmaceuticals, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc.
Achillion Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 7; Compensation: 8.